Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis
Authors:
- Christopher CarterCCChristopher Carter
- Mark DarisMDMark Daris
- Sean MoronySMSean Morony
- Casey CapparelliCCCasey Capparelli
- Angela HsiehAHAngela Hsieh
- Mingfu MaoMMMingfu Mao
- Paul KostenuikPKPaul Kostenuik
- Colin R. DunstanCDColin R. Dunstan
- David L. LaceyDLDavid L. Lacey
- Jackie Z. ShengJSJackie Z. Sheng
Open Access
- 1 February 2001
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 3 (2) , 197-205
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte SubpopulationsJournal of Bone and Mineral Research, 2000
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature OsteoclastsJournal of Cell Biology, 1999
- Clinical Effects of Raloxifene Hydrochloride in WomenAnnals of Internal Medicine, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesisin Vitro1Endocrinology, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997
- Perspectives: How many women have osteoporosis now?Journal of Bone and Mineral Research, 1995
- PamidronateDrugs, 1991